BACKGROUND: Nuclear factor-kappa B (NF-kappa B) is an important transcription factor involved in the regulation of immune responses as well as in cell proliferation and survival. An abnormal and constitutive activation of NF-kappa B is observed in many pathological states as diverse as inflammation, neurological diseases, and cancer. METHODS AND RESULTS: Termination of NF-kappa B transcription is mediated through the NF-kappa B-dependent synthesis of the I kappa B-alpha inhibitory subunit. To quantify NF-kappa B activation we measured by real-time PCR the expression of I kappa B-alpha mRNA. The PCR data perfectly matched the results obtained by Northern blot or gene reporter analysis when Jurkat leukemic T cells or HeLa carcinoma cells were stimulated with various activators of NF-kappa B, such as the cytokine tumor necrosis factor (TNF)-alpha or the phorbol ester PMA. Constitutive NF-kappa B activation in Hodgkin's lymphoma cell line could also be evaluated by this approach. Kinetic experiments in HeLa cells show that TNF stimulation first induced NF-kappa B DNA binding within 30 minutes, followed by I kappa B-alpha gene transcription 30 minutes later. Removal of TNF after stimulation resulted in a faster decrease in both NF-kappa B DNA binding activity and I kappa B-alpha mRNA levels. No accumulation or stabilization of I kappa B-alpha mRNA was detected that could bias interpretation of the results. The sensitivity of the method allowed the detection of NF-kappa B activation in stimulated normal peripheral blood lymphocytes. CONCLUSION: The real-time PCR measure of I kappa B-alpha mRNA levels is a rapid, sensitive, and powerful method to quantify the transcriptional power of NF-kappa B. It can be easily used for clinical evaluation of NF-kappa B status.
BACKGROUND:Nuclear factor-kappa B (NF-kappa B) is an important transcription factor involved in the regulation of immune responses as well as in cell proliferation and survival. An abnormal and constitutive activation of NF-kappa B is observed in many pathological states as diverse as inflammation, neurological diseases, and cancer. METHODS AND RESULTS: Termination of NF-kappa B transcription is mediated through the NF-kappa B-dependent synthesis of the I kappa B-alpha inhibitory subunit. To quantify NF-kappa B activation we measured by real-time PCR the expression of I kappa B-alpha mRNA. The PCR data perfectly matched the results obtained by Northern blot or gene reporter analysis when Jurkat leukemic T cells or HeLa carcinoma cells were stimulated with various activators of NF-kappa B, such as the cytokine tumornecrosis factor (TNF)-alpha or the phorbol ester PMA. Constitutive NF-kappa B activation in Hodgkin's lymphoma cell line could also be evaluated by this approach. Kinetic experiments in HeLa cells show that TNF stimulation first induced NF-kappa B DNA binding within 30 minutes, followed by I kappa B-alpha gene transcription 30 minutes later. Removal of TNF after stimulation resulted in a faster decrease in both NF-kappa B DNA binding activity and I kappa B-alpha mRNA levels. No accumulation or stabilization of I kappa B-alpha mRNA was detected that could bias interpretation of the results. The sensitivity of the method allowed the detection of NF-kappa B activation in stimulated normal peripheral blood lymphocytes. CONCLUSION: The real-time PCR measure of I kappa B-alpha mRNA levels is a rapid, sensitive, and powerful method to quantify the transcriptional power of NF-kappa B. It can be easily used for clinical evaluation of NF-kappa B status.
Authors: J Chiche; S Pommier; M Beneteau; L Mondragón; O Meynet; B Zunino; A Mouchotte; E Verhoeyen; M Guyot; G Pagès; N Mounier; V Imbert; P Colosetti; D Goncalvès; S Marchetti; J Brière; M Carles; C Thieblemont; J-E Ricci Journal: Leukemia Date: 2014-11-14 Impact factor: 11.528
Authors: Qiutang Li; Qingxian Lu; Virginie Bottero; Gabriela Estepa; Lisa Morrison; Frank Mercurio; Inder M Verma Journal: Proc Natl Acad Sci U S A Date: 2005-08-22 Impact factor: 11.205
Authors: Julie-Myrtille Bourgognon; Jereme G Spiers; Hannah Scheiblich; Alexey Antonov; Sophie J Bradley; Andrew B Tobin; Joern R Steinert Journal: Cell Death Differ Date: 2018-06-18 Impact factor: 15.828
Authors: Daniel T Meehan; Duane Delimont; Brianna Dufek; Marisa Zallocchi; Grady Phillips; Michael Anne Gratton; Dominic Cosgrove Journal: Hear Res Date: 2016-08-21 Impact factor: 3.208
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254
Authors: Donato A Rivas; Devin J McDonald; Nicholas P Rice; Prashanth H Haran; Gregory G Dolnikowski; Roger A Fielding Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-01-13 Impact factor: 3.619